PTH and chronic kidney disease: Many clinical studies have shown the effects of paricalcitol therapy to attenuate CKD, indicated by efficiency and safety in PTH levels and calcium-phosphorus regulation, and in the reduction in the proteinuria progression when associated with renin-angiotensin system (RAS) blocker in a non-SHPT CKD [18].